Financial Summary for the Fiscal Year Ending December 2025〔IFRS〕(Consolidated)

Performance Overview

For the fiscal year ending December 2025, consolidated revenue was JPY 18,521,234 thousand, a 60.3% decrease compared with the previous fiscal year, resulting in an operating loss of JPY 5,013,195 thousand. Net loss attributable to owners of the parent was JPY 3,749,204 thousand, representing a significant decline from the previous year's profit. The drug discovery development segment recorded revenue of JPY 2,793,300 thousand and a segment loss of JPY 5,379,999 thousand. Meanwhile, the radiopharmaceutical segment saw a slight increase in revenue to JPY 15,727,934 thousand and posted a segment profit of JPY 434,803 thousand. Cash and cash equivalents at the end of the period decreased by JPY 19,434,999 thousand compared to the previous year to JPY 28,682,933 thousand.

Outlook and Management Policy

The consolidated earnings guidance for the fiscal year ending December 2026 forecasts revenue of JPY 32,000,000 thousand, core operating income of JPY 4,600,000 thousand, operating income of JPY 4,600,000 thousand, and net income attributable to owners of the parent of JPY 3,000,000 thousand. Revenue is expected to increase 72.8% year over year, driven by existing joint research and development support fees, milestone income, PDPS® technology license revenues, upfront payments from new partnerships, and expansion of existing radiopharmaceutical products. Management policy focuses on expanding the clinical development pipeline, strategic concentration on five key areas, and growth into a global pharmaceutical company. Additionally, efforts are underway to strengthen internal controls and review governance structures, implementing preventive measures against the recurrence of inappropriate ordering and removal of reagents.